A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board

被引：21

作者：

Kuruvilla, John ^{[1
,2
]}

Assouline, Sarit ^{[3
,4
]}

Hodgson, David ^{[1
,2
]}

MacDonald, David ^{[5
,6
]}

Stewart, Doug ^{[7
,8
,9
]}

Christofides, Anna ^{[10
]}

Komolova, Marina ^{[10
]}

Connors, Joseph ^{[11
,12
]}

机构：

[1] Univ Toronto, Dept Med Oncol, Toronto, ON, Canada

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] McGill Univ, Dept Oncol, Montreal, PQ, Canada

[4] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[5] Dalhousie Univ, Div Hematol, Halifax, NS, Canada

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] Univ Calgary, Dept Oncol, Calgary, AB, Canada

[8] Univ Calgary, Dept Med, Calgary, AB, Canada

[9] Tom Baker Canc Clin, Calgary, AB, Canada

[10] New Evidence, Toronto, ON, Canada

[11] Univ British Columbia, Div Med Oncol, Vancouver, BC V5Z 1M9, Canada

[12] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷 / 02期

关键词：

Canadian; Follicular lymphoma; Guidelines; Hematology; Indolent lymphoma; Lymphoma; NON-HODGKINS-LYMPHOMA; STAGE-I-III; BENDAMUSTINE PLUS RITUXIMAB; TERM-FOLLOW-UP; FONDAZIONE ITALIANA LINFOMI; RANDOMIZED CONTROLLED-TRIAL; PROGRESSION-FREE SURVIVAL; MANTLE-CELL LYMPHOMAS; INDOLENT B-CELL; PHASE-III;

D O I：

10.1016/j.clml.2014.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in North America. Because of the heterogeneity of the disease, treatment options vary from observation to aggressive therapies or stem cell transplantation, or both. Although advances in treatment have improved outcomes, the disease remains largely incurable. In Canada, no unified national guideline exists for the front-line treatment of FL; provincial guidelines vary and are largely based on funding. There is therefore a need for evidence-based national treatment guidelines that are supported by Canadian hematologists to ensure that patients with FL have equitable access to the best available care. A group of experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of FL. Results of a systematic review of the literature are presented with consensus recommendations based on available evidence.

引用

页码：59 / 74

页数：16

共 50 条

[31] Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation [J].

Papaioannou, D. ;

Rafia, R. ;

Rathbone, J. ;

Stevenson, M. ;

Woods, H. Buckley ;

Stevens, J. .

HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (37) :1-+

[32] Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial [J].

Penalver, Francisco-Javier ;

Marquez, Jose-Antonio ;

Duran, Soledad ;

Giraldo, Pilar ;

Martin, Alejandro ;

Montalban, Carlos ;

Sancho, Juan-Manuel ;

Ramirez, Maria-Jose ;

Terol, Maria-Jose ;

Capote, Francisco-Javier ;

Gutierrez, Antonio ;

Sanchez, Blanca ;

Lopez, Andres ;

Salar, Antonio ;

Rodriguez-Caravaca, Gil ;

Canales, Miguel ;

Caballero, Maria-Dolores ;

Bello Lopez, Jose Luis ;

Carbonell, Felix ;

Ferrer Bordas, Secundino ;

Font Lopez, Patricia ;

Perez Persona, Ernesto ;

Lopez Guillermo, Armando ;

Hernandez Martin, Roberto ;

Ramon Mayans, Jose ;

Palomera, Luis ;

Perez Ceballos, Elena ;

Queizan Hernandez, Jose Antonio ;

Riaza Grau, Rosalia ;

de la Cruz, Fatima ;

Sanchez Salinas, Andres .

CANCER MEDICINE, 2019, 8 (16) :6955-6966

[33] The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study [J].

Galimberti, Sara ;

Ciabatti, Elena ;

Ercolano, Giacomo ;

Grassi, Susanna ;

Guerrini, Francesca ;

Cecconi, Nadia ;

Rousseau, Martina ;

Cervetti, Guilia ;

Mazziotta, Francesco ;

Iovino, Lorenzo ;

Falzetti, Franca ;

Falcinelli, Flavio ;

Bosi, Alberto ;

Rigacci, Luigi ;

Kovalchuk, Sofia ;

Vallisa, Daniele ;

Macchia, Lucia ;

Ciancia, Eugenio ;

Petrini, Mario .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[34] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study [J].

Hong Xiaonan ;

Song Yuqin ;

Shi Yuankai ;

Zhang Qingyuan ;

Guo Wei ;

Wu Gang ;

Li Junmin ;

Feng Jifeng ;

Kinkolykh Anastasiia ;

Knapp Andrea ;

Lin Tongyu .

中华医学杂志英文版, 2022, 135 (04) :433-440

[35] An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK [J].

Ray, Joshua A. ;

Carr, Emma ;

Lewis, Gavin ;

Marcus, Robert .

VALUE IN HEALTH, 2010, 13 (04) :346-357

[36] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study [J].

Hong, Xiaonan ;

Song, Yuqin ;

Shi, Yuankai ;

Zhang, Qingyuan ;

Guo, Wei ;

Wu, Gang ;

Li, Junmin ;

Feng, Jifeng ;

Kinkolykh, Anastasiia ;

Knapp, Andrea ;

Lin, Tongyu .

CHINESE MEDICAL JOURNAL, 2022, 135 (04) :433-440

[37] Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis [J].

Wang, Baohong ;

Ren, Cuiai ;

Zhang, Weide ;

Ma, Xiaoyan ;

Xia, Bingsen ;

Sheng, Zhixin .

HEMATOLOGICAL ONCOLOGY, 2013, 31 (01) :29-33

[38] 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years [J].

Rieger, Kathrin ;

De Filippi, Rosaria ;

Linden, Ola ;

Viardot, Andreas ;

Hess, Georg ;

Lerch, Kristina ;

Neumeister, Peter ;

Stroux, Andrea ;

Peuker, Caroline A. ;

Pezzutto, Antonio ;

Pinto, Antonello ;

Keller, Ulrich ;

Scholz, Christian W. .

ANNALS OF HEMATOLOGY, 2022, 101 (04) :781-788

[39] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis [J].

Pouyiourou, M. ;

Meyer, A. ;

Stroux, A. ;

Viardot, A. ;

La Rosee, P. ;

Maschmeyer, G. ;

Kaempfe, D. ;

Kahl, C. ;

Vucinic, V. ;

Monecke, A. ;

Hirt, C. ;

Weber, T. ;

Meissner, J. ;

Witzens-Harig, M. ;

Boettcher, S. ;

Schmalenberg, H. ;

Marks, R. ;

Prange-Krex, G. ;

Kroschinsky, F. ;

Hauf, E. ;

Keller, U. ;

Koch, K. ;

Klapper, W. ;

Herold, M. ;

Scholz, Christian W. .

ANNALS OF HEMATOLOGY, 2020, 99 (12) :2821-2829

[40] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis [J].

M. Pouyiourou ;

A. Meyer ;

A. Stroux ;

A. Viardot ;

P. La Rosée ;

G. Maschmeyer ;

D. Kämpfe ;

C. Kahl ;

V. Vucinic ;

A. Monecke ;

C. Hirt ;

T. Weber ;

J. Meissner ;

M. Witzens-Harig ;

S. Böttcher ;

H. Schmalenberg ;

R. Marks ;

G. Prange-Krex ;

F. Kroschinsky ;

E. Hauf ;

U. Keller ;

K. Koch ;

W. Klapper ;

M. Herold ;

Christian W. Scholz .

Annals of Hematology, 2020, 99 :2821-2829

← 1 2 3 4 5 →